z-logo
open-access-imgOpen Access
PAX6 overexpression is associated with the poor prognosis of invasive ductal breast cancer
Author(s) -
Xianghou Xia,
Wenjuan Yin,
Xiping Zhang,
Xiao Fang Yu,
Chen Wang,
Shumin Xu,
Wenjie Feng,
Huanming Yang
Publication year - 2015
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2015.3434
Subject(s) - breast cancer , immunohistochemistry , tissue microarray , estrogen receptor , progesterone receptor , pax6 , hazard ratio , cancer , medicine , pathology , lymph node , oncology , biology , cancer research , confidence interval , transcription factor , biochemistry , gene
Paired box 6 (PAX6) plays a significant role in the development of human neuroectodermal epithelial tissues. Previous studies have suggested that the PAX6 promoter is hypermethylated in breast cancer and that it is involved in breast cancer cell proliferation. The present study aimed to investigate the expression of PAX6 in invasive breast cancer tissues, and to evaluate its prognostic significance. Immunohistochemistry (IHC) was used to detect PAX6 expression on a breast cancer tissue microarray containing tissues from 111 patients. Associations of PAX6 expression with staging and prognosis were analyzed. PAX6 was mainly expressed in the nucleus. The PAX6 staining intensity was not associated with age, histological grade, lymph node status, tumor size, or progesterone receptor and human epidermal growth factor receptor 2 expression (all P>0.05). A high level of PAX6 staining was more frequent in estrogen receptor (ER)-negative cases compared with ER-positive cases (43.9 vs. 25.7%; P=0.049). After a median follow-up time of 110 months, the patients with low PAX6 expression exhibited an improved survival rate compared with the patients with high PAX6 expression (P<0.001). Cox analysis showed a worse survival rate in the patients with high PAX6 staining (hazard ratio, 3.458; 95% confidence interval, 1.575-7.593; P=0.002). In conclusion, high tumor PAX6 staining intensity by IHC was associated with a poor prognosis in breast cancer patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here